MAPK3 and Parkinson disease: In addition, in PD animal models and/or L-DOPA treatment, increased DARPP-32-Thr-34 phosphorylation and activation of ERK1/2 in the striatum are related to behavioral abnormalities [71]–[73], [125]–[127].